Tag: stem cell treatments
In rodent studies, method reduced likelihood of further spinal cord trauma while delivering large doses of potentially reparative stem cells; the approach may have utility for multiple neurodegenerative conditions
Writing in the journal Stem Cells Translational Medicine, an international research team, led by physician-scientists at University of California San Diego School of Medicine, describe a new method for delivering neural precursor cells (NSCs) to spinal cord injuries in rats, reducing the risk of further injury and boosting the propagation of potentially reparative cells.
In 2016, Chris’ spine was severely injured in a biking accident. Now he has regained use of his arms after receiving a novel cell treatment at Rush.
Controversy surrounds the link between Australian of the Year Alan Mackay Sim’s research and a Polish team who restored mobility for a paraplegic man.
For many people suffering from disabling conditions, such as Parkinson’s disease, spinal injury and paralysis, multiple sclerosis, macular degeneration, heart disease, renal failure and even cancer, announcements in the press around breakthroughs in stem cell research undoubtedly bring hope.
The challenge remains how to accurately communicate what is genuinely possible in terms of therapies and what we scientists hope might be possible but do not yet have strong evidence for.
Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and been given approval to expand the therapy to a larger group of patients with a much higher dose of cells.
Asterias Biotherapeutics announced that its Data Monitoring Committee (DMC) has reviewed the safety data from the first two groups of patients treated and found no problems or adverse side effects. One group of three patients was given 2 million cells. The second group of five patients received 10 million cells. Asterias is now cleared to enroll another 5-8 patients with 20 million cells.
When using this form of gene editing, Cedars-Sinai scientists can more efficiently insert reporter genes that glow when a stem cell turns into a specific cell of the body. 5 billion cells of the heart.
The team foresees their findings being implemented in the regrowth of cells lost during heart attack. And this might tremendously benefit the patients who undergo these kinds of procedures.
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions.